INTRODUCTION
Coumadin (warfarin) is a vitamin K antagonist, which for many years was the sole oral anti-coagulant treatment. It is well established that Coumadin can aid in preventing primary and secondary venous and arterial thromboembolic events (Kimmel et al., 2007) . Effective treatment with Coumadin requires monitoring with repetitive blood tests for prothrombine time and determination of the international standardised ratio (INR) . Although Coumadin is an important therapy, it remains a challenging drug since it has a narrow therapeutic range (Hylek and Singer, 1994; Hylek et al., 1996) and requires frequent monitoring, the results of which can be influenced by genetic factors, drugs, food intake, nutritional supplements, and diseases states (Ansell et al., 2008) .
Compliance (adherence to treatment) is the extent to which patients take their prescribed medical treatment or the level of patient participation in an agreed-on medication regimen (Osterberg and Blaschke, 2005) . Low compliance to a prescribed treatment can result in negative health outcomes. In a meta-analysis of 19 000 patients with acute or chronic diseases it was found that the proportion of patients achieving PROCEEDINGS OF THE LATVIAN ACADEMY OF SCIENCES. Section B, Vol. 71 (2017) , No. 1/2 (706/707), pp. 14- 21. DOI: 10.1515 21. DOI: 10. /prolas-2017 a better outcome was 26% higher in adherent versus nonadherent patients (DiMatteo et al., 2002) . A meta-analysis that examined the time that patients spent in the therapeutic range of INR due to Coumadin treatment showed that patients from anticoagulant clinics were 66% more compliant to the treatment, while patients treated in usual care were only compliant in 57% of the cases (van Walraven et al., 2006) . Kimmel et al. (2007) demonstrated that 36% of patients defined as having low compliance to Coumadin were at a higher risk (OR = 2.10 95 %CI 1.48-2.96) to have INR levels below the target range. Low or non-compliance with Coumadin treatment may lead to a 16-fold increase in risk for thrombosis and bleeding (Osterberg and Blaschke, 2005) . In another study that included 4188 patients with atrial fibrillation (AF) it was demonstrated that 26.3% of patients who were started on Coumadin treatment discontinued therapy within the first year of treatment (Fang et al., 2010) . In a study by Ganz et al. (2000) that investigated compliance to Coumadin treatment after vein thromboembolism (VTE) or pulmonary emboli events it was found that 25% of patients used oral anti-coagulation therapy for less than 90 days, the minimal recommended time for therapy (Ganz et al., 2000) . Another study that also investigated patients with VTE found that 63% of these patients had stopped Coumadin therapy within a one-year period, and among them 12% had discontinued therapy within three months after treatment initiation (Deitelzweig et al., 2010) . Finally, in a study investigating 8040 patients with high risk for recurrent VTE it was observed that 76.9% of them were non-compliant with Coumadin therapy and 51.5% had completely discontinued the therapy (Chen et al., 2013) .
Several studies identified risk factors related to low compliance for different drugs. In general, predictors for low compliance to therapy include disease-related factors, such as treatment of chronic disease (Haynes et al., 2002; Jackevicius et al., 2002) , treatment of asymptomatic disease (Sewitch et al., 2003) , side effects of medication (van Servellen et al., 2002) , complexity of treatment (Ammassari et al., 2002) ; psychological factors (Ammassari et al., 2002; Stilley et al., 2004) , and cognitive impairment (Okuno et al., 2001; Stilley et al., 2004) . Another group of factors that can affect drug compliance are related to contact with medical staff, such as poor physician-patient relationship (Urquhart, 2002; van Servellen et al., 2002) , inadequate follow-up or discharge planning, and missed appointments (Lacro et al., 2002) . Factors that can improve compliance to Coumadin are increased patient education, availability and accessibility of the clinic (Haynes et al., 2002) , and improvement of physician-patient communication (Misdrahi et al., 2002) .
In this study we aimed to determine risk factors affecting patient compliance to Coumadin in a cohort of patients from the largest health maintenance organisation (HMO) in Israel for eight years of follow-up, and using additional personal interviews. We attempted to build a Total Compliance Index that explains patient behaviour regarding factors that can affect their compliance to Coumadin treatment.
METHODS
Study design and population. The aim of the study was to evaluate a maximum amount of factors that might affect compliance to Coumadin treatment. Partly these factors can be identified using information stored in databases of health services, but others, such as regarding patient-staff relationships, additional drug insurance of patient, or selfestimation of quality of life (QOL) of the patient can be investigated only by personal interviews. For this reason, the proposed study was composed of two phases:
Phase 1: Retrospective phase with follow-up during 1.01.02 till 31.12.09 -analysis of "Clalit" health care service (the largest HMO in Israel) datasets. The "Clalit" database includes 350 000 patients; of them 7109 (SD 1914 ) patients per year of study met inclusion criteria and were used in the analysis in Phase 1. All patients over 30 years of age receiving Coumadin treatment during the study period through "Clalit" health care services in the southern region of Israel were included in this phase of the study. In order to verify long-term Coumadin use (at least two years), we analysed the data of patients starting from 2002, even though the data was collected from 2000. Patients with malignancies, patients after accidents, and patients who required a short period of Coumadin treatment (less than three months) were excluded from the analysis.
Phase 2: A cross-sectional study during 1.1.09 to 31.12.09, in addition to the analysis of datasets, was conducted using telephone interviews. This phase of the study included participants that received Coumadin treatment for no less than two years before 2009, were over 30 years old, and had provided updated telephone numbers. We excluded patients who did not understand Hebrew, English, Arabic, or Russian languages. The study sample for the Phase 2 (phone interview) was 689 patients.
Ethical approval. The study was approved in 2002 by the Helsinki committee of Soroka University Medical Centre in Be'er-Sheva, Israel. For security reasons identification data for patients were recoded into a study identification number according to the Helsinki committee guidelines. For Phase 2 of the study, additionally verbal consent of the patient was received at the beginning of the conversation. Data assessment. Data regarding patients characteristics (date of birth/death, gender, place of residence), purchasing Coumadin and different groups of drugs (type and dates), performing INR tests (dates, number of tests and results), and health care utilisation (number of doctor visits, hospitalisation days) was obtained from "Clalit" computerised database.
Data regarding socio-economic status according to residence of living was obtained from the central bureau of statistics. Missing data for socio-economic status was obtained via telephone interviews.
Phone interviews were conducted by interviewers (10 persons) who were medical students, trained by the research coordinator after signing a confidentiality agreement. Interviewers received instruction about the questionnaires and study aims. The first five calls were made under supervision of the coordinator, which included checking the forms and listening to randomly selected tapes of interviews. If the patient was unreachable, one more attempt was made.
The questionnaire for the telephone interview included socio-demographic details, such as the level of education (elementary school -up to 8 years, high school -12 years, and academic or professional education -more than 12 years), income, place of birth; questions regarding QOL SF12 (Anonymous, 1994) and the depression, anxiety, stress scale (DASS) adapted for the effect of anticoagulation treatment for Coumadin patients (Samsa et al., 2004) . Additional questions were added by the research team: ways of receiving INR results, reasons for not purchasing the drug, time of taking the drug, the extent of satisfaction from patient-physician and patient-staff relationships, and having additional health insurance. Before the pilot study, the developed questionnaire containing 50 questions in Hebrew was translated to Russian, English, and Arabic by two independent translators. This was adapted to 40 questions based on interviewer notes. Questions on SF-12 related to QOL were divided into physical and mental scores. The data was entered into an electronic database. Quality control was achieved by constant typing, reviewing a sample of cases and rechecking 5% of the patients by performing a second interview after obtaining consent.
Study variables
The following independent variables were used:
1. Socio-demographic variables: age, gender, socio-economic status, income, nationality, place of birth, language, immigration year, education, additional health insurance. The following dependent variables were used:
The Total Compliance Index was defined using three variables (by a board-certified haematologist): number of Coumadin purchases (40%), compliance to perform INR tests (40%), and average INR value (20%).
The number of Coumadin purchases was calculated per month. Performing one or more purchases during one month was given a score of one, while non-purchasingzero. The total number of purchases per year was divided by 12 to calculate the mean number of purchases per month. It should be noted that in Israel, Coumadin can be prescribed for a three-month period. Therefore, the minimum number of purchases made per year is 4 (received a value of one).
Compliance to perform an INR test was calculated as the number of tests performed during one month; performing at least one test a month received a value of one, and lesszero value. The total number of tests during a year was calculated, and then divided by 12 to estimate mean number of tests per month.
Average INR value. The targeted value of INR is 2 to 3 (Ansell et al., 2008) . The INR test result for the Compliance Index was calculated as dichotomous variable. If the mean INR of a patient was between 2 to 3, the patient received 1 point, if not -0 points. The test result index was calculated for each patient by dividing the total number of points during one year, by the number of tests performed during the same year. Since the recommended INR testing period is four weeks after achieving a stable dose, the minimum number of INR tests performed during a year was eight (received a value of one).
For the purpose of this study we defined a "compliant patient" as scoring 73% or more on the Total Compliance Index scale (the 20 th percentile of the calculated Total Compliance Index), and with less than 73% on the scale as non-compliant. The proportions of compliant and non-compliant patients did not change when this threshold was lowered or raised by 10% on the scale.
Statistical analysis. Descriptive statistics of study variables included means and standard deviations for normally distributed quantitative variables; for quantitative variables with non-normal distribution the median and range were presented. For qualitative variables the distribution (N, %) were presented. The univariate analysis of possible relations between dependent variables and each of the independent variables was performed using the Mann-Whitney test, or Chi-square (Exact Fisher test) for qualitative variables. Pearson correlation coefficients between Physical and Mental factors of the SF-12 questionnaire were determined. Variables that were significantly associated in the univariate analysis with the Total Compliance Index were included in multiple logistic regression, and p values of £ 0.05 were considered to be statistically significant. Statistical analysis was performed using the SPSS 18 th version. *No significant differences between the sample and all the study population were found **Only for variables received both for total population and studied sample Use of drugs. Both for Phase 1 and Phase 2, the majority of drugs were from group C (mean 12.25 ± 7.55 per year).
RESULTS
Other groups of drugs used were: 0 group (mean 0.87 ± 1.32); A group (mean 6.34 ± 5.38); B group (mean 5.44 ± 3.46); D group (mean 2.25 ± 3.11); G group (mean 1.22 ± 2.29), and H group (mean 1.23 ± 2.29). The total median number of drugs that one patient used simultaneously without mention of drug categories was 41 (range 0 to 132).
DISCUSSION
Coumadin is an essential lifesaving drug which necessitates full compliance from patients; however, our eight-year follow-up prospective study showed that more than 50% patients were non-compliant. In this study we developed a Coumadin Total Compliance Index and found that good compliance was related to older age, frequent doctor visits, patients involved in their own care, and patients taking cardiovascular medication. As newer anti-coagulation drugs are increasingly used, there is a need to investigate the components of the compliance index.
During the study from 2002 to 2009, the compliance for Coumadin-treated patients was related with age, which was found to be the strongest predictor of non-compliance to Coumadin usage. Age was evaluated in various prior studies. In contrast to our results, most studies showed statistically significant reduction in Coumadin use with advanced age. Coumadin usage decreased sharply after 75 years of age (DeWilde et al., 2006) . The reason for that difference might be because younger AF patients do not receive Coumadin as commonly as older patients. Older age (³85 years), as well as younger age (<55 years) decrease the use of warfarin (Johnston et al., 2003) . Therefore, the association between age and Coumadin is nonlinear. In our study, the majority of patients were aged 55-80 (70%), and consequently we did not examine the population group for which age in which the Coumadin-age relationship has opposite nature.
Our results are similar to previous studies that showed primary care in a giver-patient relationship to be a major interventional point for treatment enhancement. Previous studies have showed that inadequate follow-up (Sewitch et al., 2003) , poor physician-patient relationship (Lacro et al., 2002; Urquhart, 2002) and missed appointments (Stilley et al., 2004) are all related to low medical treatment compliance. Studies that focused on Coumadin compliance have found that improving physician-patient communication (Misdrahi et al., 2002) results in improved compliance to Coumadin treatment. All these findings are in line with ours.
Another important predictor for Coumadin compliance that was demonstrated in our study was the level of patient involvement in their own care. Patients who received INR results from the clinic had better compliance. These results support past studies that showed low compliance in patients who had lack of belief in the benefit of the treatment (Okuno et al., 2001; Lacro et al., 2002) , or a lack of insight into the illness (Lacro et al., 2002) . In contrast, greater understanding of why medication was prescribed and anticipated side effects was found as a predictor for enhanced compliance (Bushnell et al., 2011) .
In our study, receiving drugs from Group C (Cardiovascular System drugs category) in addition to Coumadin was found to improve medical compliance. Data on the association between cardiovascular diseases as congestive heart failure and ischemic heart disease with Coumadin compliance was demonstrated in various studies and supports these findings. It is assumed that having increased risk of stroke due to other cardiovascular morbidities increases both patient and care-giver focus on stroke prevention with anti-coagulation treatment (Johnston et al., 2003) . Although we did not observe significant differences between compliant and noncompliant patients regarding hospitalisation days, in Phase 2 of the study non-compliant patients were hospitalised almost twice as long (at average) as were compliant patients, and they used the health care services approximately twice as much as compliant patients.
Limitations of the study
Total Compliance Index. The Total Compliance Index was computed using three different variables: number of purchases of Coumadin, compliance to perform INR tests, and average INR values. For a part of the patients we had missing data for one or two of these variables, and thus it was impossible to calculate the index for these patients. This resulted in a difference between the number of patients that used Coumadin and were eligible for the study, and the number of patients with calculated Total Compliance Index. However, we did not observe differences in individual and treatment-related characteristics between patients with and without missing data. Socio-economic status. The city of residence was obtained for all patients. The socio-economic status was estimated using the Central Bureau of Statistics codes. Thus, the socio-economic status of the patients was estimated and was not specific to the patient. In the case of missing data for the place of patient residence, obtained data during the phone interview for the study sample of Phase 2, but we had no possibility to do this for the entire population.
Strengths of the study. The first strength of the study was that the study population included patients who used Coumadin for a period of at least for two years; hence we included only patients who were familiar to Coumadin treatment. This improves the validity of our study. Another important strength of this study was the use of questionnaires in addition to the medical records. This allowed to extract data that were not available in medical records, and allowed to demonstrate that variables such as distance to the clinic, QOL, medical side effects and patient-doctor relationship had no statistical effect on compliance.
CONCLUSIONS
In this study we developed a Coumadin Total Compliance Index. We offer this Total Compliance Index to be utilised for other drugs as well. Although Coumadin is a lifesaving drug, non-compliance rates were higher than 50% of the studied group of patients. Use of the compliance model showed that older age, doctor visits, INR check-up in the clinic and cardiovascular medication usage were associated with better Coumadin compliance.
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